Impact of radiotherapy for high-risk neuroblastoma: a Children's Cancer Group study
- PMID: 12694821
- DOI: 10.1016/s0360-3016(02)04506-6
Impact of radiotherapy for high-risk neuroblastoma: a Children's Cancer Group study
Abstract
Purpose: To assess the effect of local radiation administered to primary disease sites in children with high-risk neuroblastoma.
Materials and methods: A total of 539 eligible patients were entered on protocol CCG-3891, consisting of chemotherapy, primary surgery, and 10 Gy of external beam radiation therapy (EBRT) to gross residual disease, followed by randomized assignment to continuation chemotherapy (CC) or autologous bone marrow transplantation (ABMT). ABMT patients received total body irradiation (TBI).
Results: Estimated event-free survival and overall survival at 5 years were 25% +/- 2% and 35% +/- 2%, respectively. Estimated 5-year locoregional recurrence rates were 51% +/- 5% and 33% +/- 7% for CC and ABMT patients (p = 0.004). For patients who received 10 Gy of EBRT to the primary, the addition of 10 Gy of TBI and ABMT decreased local recurrence compared with CC (22% +/- 12% and 52% +/- 8%, p = 0.022). EBRT did not increase acute toxicity, except for increased total parenteral nutrition administration.
Conclusions: In combination with EBRT to the primary tumor site, the addition of 10 Gy of TBI as a component of high-dose chemotherapy with ABMT improved local control compared with CC without TBI. Results suggest a dose-response relationship for local EBRT. Short-term toxicity of local EBRT is limited.
Similar articles
-
Autologous bone marrow transplantation for advanced neuroblastoma using teniposide, doxorubicin, melphalan, cisplatin, and total-body irradiation.J Clin Oncol. 1995 Nov;13(11):2789-95. doi: 10.1200/JCO.1995.13.11.2789. J Clin Oncol. 1995. PMID: 7595740
-
Consolidation chemoradiotherapy and autologous bone marrow transplantation versus continued chemotherapy for metastatic neuroblastoma: a report of two concurrent Children's Cancer Group studies.J Clin Oncol. 1996 Sep;14(9):2417-26. doi: 10.1200/JCO.1996.14.9.2417. J Clin Oncol. 1996. PMID: 8823319
-
High-dose melphalan with 6-hydroxydopamine-purged autologous bone marrow transplantation for poor-risk neuroblastoma.Cancer. 1991 Jul 15;68(2):242-7. doi: 10.1002/1097-0142(19910715)68:2<242::aid-cncr2820680204>3.0.co;2-p. Cancer. 1991. PMID: 1906368
-
Autologous bone marrow transplantation in paediatric solid tumours.Clin Haematol. 1986 Feb;15(1):187-203. doi: 10.1016/s0308-2261(86)80011-x. Clin Haematol. 1986. PMID: 3516489 Review.
-
Adult medulloblastoma: multiagent chemotherapy.Neuro Oncol. 2001 Jan;3(1):29-34. doi: 10.1093/neuonc/3.1.29. Neuro Oncol. 2001. PMID: 11305414 Free PMC article. Review.
Cited by
-
Osteochondroma in long-term survivors of high-risk neuroblastoma.Cancer. 2015 Jun 15;121(12):2090-6. doi: 10.1002/cncr.29316. Epub 2015 Feb 27. Cancer. 2015. PMID: 25728463 Free PMC article.
-
Local MRI before and after Tumor Resection in Neuroblastoma: Impact of Residual Disease on Event Free Survival.J Clin Med. 2023 Nov 24;12(23):7297. doi: 10.3390/jcm12237297. J Clin Med. 2023. PMID: 38068349 Free PMC article.
-
Neuroblastoma.Pediatr Blood Cancer. 2021 May;68 Suppl 2(Suppl 2):e28473. doi: 10.1002/pbc.28473. Pediatr Blood Cancer. 2021. PMID: 33818884 Free PMC article. Review.
-
Phase I trial of 90Y-DOTATOC therapy in children and young adults with refractory solid tumors that express somatostatin receptors.J Nucl Med. 2010 Oct;51(10):1524-31. doi: 10.2967/jnumed.110.075226. Epub 2010 Sep 16. J Nucl Med. 2010. PMID: 20847174 Free PMC article. Clinical Trial.
-
Markedly improving survival of neuroblastoma: a 30-year analysis of 1,646 patients.Pediatr Surg Int. 2007 Jul;23(7):637-46. doi: 10.1007/s00383-007-1933-7. Epub 2007 May 3. Pediatr Surg Int. 2007. PMID: 17476512
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical